144 related articles for article (PubMed ID: 30927971)
1. Germline polymorphisms and the risk of therapy-related myeloid neoplasms.
Takahashi K
Best Pract Res Clin Haematol; 2019 Mar; 32(1):24-30. PubMed ID: 30927971
[TBL] [Abstract][Full Text] [Related]
2. TP53 and therapy-related myeloid neoplasms.
Chung J; Sallman DA; Padron E
Best Pract Res Clin Haematol; 2019 Mar; 32(1):98-103. PubMed ID: 30927980
[TBL] [Abstract][Full Text] [Related]
3. What's new in the pathogenesis and treatment of therapy-related myeloid neoplasms.
Voso MT; Falconi G; Fabiani E
Blood; 2021 Sep; 138(9):749-757. PubMed ID: 33876223
[TBL] [Abstract][Full Text] [Related]
4. Stem cell damage after chemotherapy- can we do better?
Tang J; Zhu N; Rao S; Carlson KS
Best Pract Res Clin Haematol; 2019 Mar; 32(1):31-39. PubMed ID: 30927973
[TBL] [Abstract][Full Text] [Related]
5. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.
Baranwal A; Hahn CN; Shah MV; Hiwase DK
Curr Hematol Malig Rep; 2022 Dec; 17(6):254-265. PubMed ID: 35986863
[TBL] [Abstract][Full Text] [Related]
6. Myeloid malignancies after treatment for solid tumours.
Guru Murthy GS; Abedin S
Best Pract Res Clin Haematol; 2019 Mar; 32(1):40-46. PubMed ID: 30927974
[TBL] [Abstract][Full Text] [Related]
7. Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
Hu AY; Zhou T
Br J Haematol; 2019 Jan; 184(1):8. PubMed ID: 30407632
[No Abstract] [Full Text] [Related]
8. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
[No Abstract] [Full Text] [Related]
9. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
Pemmaraju N; Kantarjian H; Nastoupil L; Dupuis M; Zhou L; Pierce S; Patel KP; Masarova L; Cortes J; Verstovsek S
Blood; 2019 May; 133(21):2348-2351. PubMed ID: 30796023
[TBL] [Abstract][Full Text] [Related]
10. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
11. Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis.
Liu YC; Illar GM; Al Amri R; Canady BC; Rea B; Yatsenko SA; Geyer JT
Mod Pathol; 2022 May; 35(5):625-631. PubMed ID: 34873304
[TBL] [Abstract][Full Text] [Related]
12. Preface.
Michaelis LC
Best Pract Res Clin Haematol; 2019 Mar; 32(1):1-2. PubMed ID: 30927968
[No Abstract] [Full Text] [Related]
13. Micronuclei, dmin chromosomes and MYC amplifications as a singular presentation of myeloid malignancies.
Montoro MJ; Rivero E; Teixidó M; Rodriguez Y; Chávez C; Salamero O; Navarrete M; Talavera E; Ortega M; Valcárcel D
Br J Haematol; 2020 Oct; 191(1):e19-e22. PubMed ID: 32627175
[No Abstract] [Full Text] [Related]
14. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
[No Abstract] [Full Text] [Related]
15. Platelet miR-28 expression level and thrombocytosis in MPN patients.
Stolyar MA; Gorbenko AS; Olkhovskiy IA
Int J Lab Hematol; 2019 Apr; 41(2):e43-e45. PubMed ID: 30480878
[No Abstract] [Full Text] [Related]
16. Impact of Notch disruption on myeloid development.
Francis OL; Chaudhry KK; Lamprecht T; Klco JM
Blood Cancer J; 2017 Aug; 7(8):e598. PubMed ID: 28841212
[No Abstract] [Full Text] [Related]
17. ZBTB7A links tumor metabolism to myeloid differentiation.
Redondo Monte E; Kerbs P; Greif PA
Exp Hematol; 2020 Jul; 87():20-24.e1. PubMed ID: 32525064
[TBL] [Abstract][Full Text] [Related]
18. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
19. Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci.
Carraway HE; LaFramboise T
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101191. PubMed ID: 33038980
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
Miller LH; Qu CK; Pauly M
Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
